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Abstract
Circular RNAs (circRNAs) are covalently closed endogenous molecules with tissue- and disease-speciﬁc expression
patterns, which have potential as diagnostic and prognostic biomarkers in cancer. The molecules are formed by a
backsplicing event linking the 3′-end of an exon to the 5′-end of the same or an upstream exon, and they exert diverse
regulatory functions important in carcinogenesis. The landscape of circRNA expression has not been characterized in B-cell
malignancies, and current methods for circRNA quantiﬁcation have several limitations that prevent development of
clinically applicable assays. Here, we demonstrate that circRNAs can be accurately quantiﬁed without enzymatic reactions or
bias using color-coded probes (NanoString technology). First, we performed high-throughput RNA sequencing (RNA-seq)
of several mantle cell lymphoma and multiple myeloma cell lines to proﬁle the genome-wide landscape of circRNA
expression. We detected several circRNAs known to be deregulated in other cancers and identiﬁed a novel circRNA from
the IKZF3 gene. Based on these data, we selected 52 unique circRNAs for which we designed color-coded probes spanning
their speciﬁc backsplicing junctions. These circRNAs were quantiﬁed in cell lines and patient samples from several different
B-cell malignancies (mantle cell lymphoma, multiple myeloma, follicular lymphoma, diffuse large B-cell lymphoma, Burkitt
lymphoma and chronic lymphocytic leukemia) simultaneously using the NanoString technology. The circRNA expression
proﬁles obtained could distinguish different B-cell malignancies, and conﬁrmed the presence of the novel circRNA derived
from IKZF3. The NanoString assays were speciﬁc for circRNA detection and data were more reproducible and quantitatively
more accurate than RNA-seq data. In addition, we obtained high-quality data on severely degraded RNA samples from
formalin-ﬁxed, parafﬁn-embedded (FFPE) tissues. Together, we provide a map of circRNA expression in B-cell
malignancies and present an enzyme-free digital counting methodology, which has the potential to become a new gold
standard for circRNA quantiﬁcation.
Introduction
Circular RNA (circRNA) is a recently discovered compo-
nent of the non-coding genome adding yet another layer of
complexity to the gene regulation involved in cell differ-
entiation and homeostasis, as well as in the development of
various diseases such as cancer [1, 2]. CircRNAs are
formed by a backsplicing event covalently linking the 3′-
end of an exon to the 5′-end of the same or an upstream
exon [3]. Most circRNAs originate from a host gene and
their biogenesis is promoted by ﬂanking homologous
inverted repeats (Alu repeats in humans) bringing the splice
sites in close proximity. A common feature of circRNAs is
their high stability owing to the lack of free ends, which
renders them resistant to exonucleolytic degradation [4],
and many of their diverse functions are directly related to
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this, including sponging of miRNAs [5–7] and protein
scaffolding [8, 9]. CircRNAs may also regulate host gene
expression either directly by functioning as transcriptional
enhancers or indirectly by competing with linear splicing
[10, 11]. Others function as global or speciﬁc regulators of
protein translation [12, 13], and some even function as
templates for translation [14–16].
A number of studies have reported differential expres-
sion of speciﬁc circRNAs in various tumor tissues, and due
to the high stability of these molecules they are promising
biomarkers in cancer diagnostics [1]. However, knowledge
on circRNA expression and function in hematologic
malignancies is sparse [3, 17, 18], and these molecules have
not previously been studied in B-cell malignancies. These
diseases arise at various stages of B-cell development,
maturation and differentiation, most from B-cells in the
germinal center (GC) [19], whereas chronic lymphocytic
leukemia (CLL) is thought to arise from memory B-cells in
peripheral blood [20]. The majority of mantle cell lym-
phomas (MCLs) arise from naive B-cells before they enter
the GC [21], and multiple myeloma (MM) develops from
memory B-cells or plasmablasts that migrate to the bone
marrow and differentiate into malignant plasma cells [22].
Several methodological obstacles impair the detection
and quantiﬁcation of circRNAs [1, 23]. First, circRNAs lack
poly(A) tails and are therefore discarded during library
preparation for high-throughput RNA sequencing (RNA-
seq) when using protocols that rely on a poly(A) puriﬁca-
tion step for removal of ribosomal RNA (rRNA). Thus,
most publically available RNA-seq data sets, including the
majority of data from The Cancer Genome Atlas (TCGA),
cannot be analyzed for circRNA expression. Second, it is
necessary to actively search for circRNAs as sequencing
reads mapping to the backsplicing junctions of circRNAs
are discarded in standard bioinformatics algorithms,
because they do not map to the linear reference genome.
Similarly, conventional reverse transcription-quantitative
PCR (RT-qPCR) assays do not distinguish circular from
linear RNA when using the linear genome as template for
primer design. Even when actively searching for circRNAs,
methodological challenges like template switching and
rolling circle ampliﬁcation during RT and ampliﬁcation bias
during PCR may hamper the results [1, 23, 24]. Therefore,
the circular nature of the transcripts needs to be validated. A
commonly used validation method utilizes the fact that
circRNAs are generally resistant to degradation by RNase
R, an exonuclease, which degrades linear RNA. However,
variability between individual RNase R treatments has been
observed [4], and some circRNAs seem to be sensitive to
RNase R [25]. Because of these problems, northern blotting,
which does not rely on RT and PCR ampliﬁcation, is cur-
rently regarded as the gold standard for circRNA detection.
However, this method requires large quantities of RNA, is
labor intensive and not quantitatively accurate. Taken
together, no current methods have the capability of accu-
rately quantifying circRNAs and there is no consensus on
how to evaluate or account for the possible bias introduced
during RT and PCR ampliﬁcation of RNA-seq and RT-
qPCR protocols.
Intriguingly, a relatively novel digital counting technol-
ogy, termed NanoString, is completely free of any enzy-
matic reactions and accurate for quantifying linear mRNAs
[26]. The technology is based on a dual-probe hybridization
using a biotinylated capture probe and a unique color-coded
reporter probe. A combination of ﬂuorophores on the
reporter probe provides a unique barcode for each tar-
get, allowing for multiplexing of up to 800 targets in one
experiment [27]. Because the probes only target short RNA-
sequences and no RT or ampliﬁcation steps are involved,
this method is particularly suitable for analyzing highly
degraded RNA isolated from formalin-ﬁxed parafﬁn-
embedded (FFPE) tissues, which are often routinely stored
in pathology departments along with patient data [26, 28].
However, the NanoString technology has not previously
been used for the detection of circRNA.
In this study, we proﬁled the genome-wide landscape of
circRNA expression in MCL and MM cell lines using
RNA-seq. Based on these data, we designed a panel of
NanoString assays for 52 unique circRNAs to analyze on
the nCounter SPRINTTM Proﬁler from NanoString Tech-
nologies. To investigate the potential of this technology for
circRNA detection and quantiﬁcation, we analyzed high-
quality RNA samples and RNase R-treated samples from
the MCL cell lines, as well as low-quality RNA derived
from the same cell lines after formalin ﬁxating and parafﬁn
embedding the cells. In addition, we analyzed RNA isolated
from several different cell lines from B-cell malignancies, as
well as paired fresh frozen and FFPE patient samples.
Finally, we compared the NanoString data with RNA-seq-
and RT-qPCR data.
Materials and methods
Cell lines, patient samples and ethical
considerations
MCL cell lines (REC-1 and UPN2), diffuse large B-cell
lymphoma (DLBCL) cell lines (HT, OCI-Ly3, Toledo and
U2932), Burkitt lymphoma (BL) cell lines (Raji and
Ramos) and MM cell lines (RPMI-8826 and OPM2) were
cultured in RPMI-1640 with 10% fetal bovine serum (FBS).
The MM cell line (MOLP2) was cultured in PRMI-1640
with 20% FBS. The MCL cell lines (Z138 and Granta-519)
were cultured in Iscove’s modiﬁed Dulbecco’s medium
(IMDM) with 10% Horse Serum and in Dulbecco’s
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modiﬁed Eagle’s medium (DMEM) with 10% FBS,
respectively. The MM cell line (NCI-H929) was cultured in
RPMI-1640 with 1 mM sodium pyruvate and 50 µM 2-
mercaptoethanol and 10% FBS, whereas the MM cell line
(JJN3) was cultured in a medium containing 40% IMDM,
40% DMEM and 20% FBS.
Paired fresh frozen and FFPE tissue samples from
archived lymph nodes were obtained from ﬁve patients with
MCL, three patients with CLL, three patients with follicular
lymphoma (FL) grade 1–2 and two patients with DLBCL.
Specimens were collected between 1990 and 2008 at the
Department of Pathology, Rigshospitalet, and patients were
diagnosed according to the WHO lymphoma classiﬁcation.
This study was performed in accordance with the
Declaration of Helsinki and Danish legislation.
Formalin-ﬁxation and parafﬁn embedding of cell
lines
Formalin-ﬁxation and parafﬁn embedding of cells was car-
ried out on a Peloris tissue processor (Leica Biosystems,
Wetzlar, Germany) with a ﬁxation time of approximately
12 h after assembly of cell pellets by addition of human
plasma and bovine thrombin (BIOFAC, Kastrup, Denmark)
along with a Mayer’s hematoxylin staining for visualization.
RNA isolation and integrity assessment
RNA from cell lines was isolated using the Allprep DNA/
RNA/miRNA universal kit (Qiagen, Hilden, Germany).
For RNA isolation of FFPE cell lines, the Allprep DNA/
RNA FFPE kit (Qiagen) was used following a xylene
deparafﬁnization. RNA from fresh frozen patient samples
was isolated with the RNeasy mini kit (Qiagen). Tissues
were disrupted using the rotor-stator homogenizer Dispomix
(Xiril, Hombrechtikon, Switzerland). RNA from the FFPE
patient samples was isolated from two freshly cut sections of
20 µm for each sample using the RNeasy FFPE kit (Qiagen)
following a xylene deparafﬁnization. Regardless of the kit
used, on-column DNase (Qiagen) treatment was performed.
RNA concentrations were assessed using a Nano-
drop2000c (Thermo Fisher Scientiﬁc, Waltham, MA, USA)
instrument and RNA integrity number (RIN) value was
measured on the Bioanalyzer 2100 (Agilent Technologies,
Santa Clara, CA, USA) using the RNA Nano 6000 kit
(Agilent Technologies). Representative results are shown in
Supplementary Figure 1 and RIN values are listed in Sup-
plementary Table 1.
High-throughput RNA-seq
One microgram of total RNA was rRNA depleted using the
Ribo-Zero rRNA Removal Kit (Human, Mouse, Rat)
(Epicentre, Madison, WI, USA) followed by a puriﬁcation
step using AMPure XP Beads (Beckman Coulter, Brea, CA,
USA). Sequencing libraries were generated using the
ScriptSeq v2 RNA-Seq Library Preparation Kit (Epicentre)
using 12 PCR cycles for ampliﬁcation. Puriﬁcation was
performed using AMPure XP Beads (Beckman Coulter).
The ﬁnal libraries were quality controlled on the 2100
Bioanalyzer (Agilent Technologies) and quantiﬁed using
the KAPA library quantiﬁcation kit (Kapa Biosystems,
Wilmington, MA, USA). RNA-seq was performed on the
HiSeq 4000 system (Illumina, San Diego, CA, USA) at the
Beijing Genomics Institute (BGI) using the 100 paired-end
sequencing protocol with nine samples pooled on one lane.
RNA-seq data analysis
Sequencing data were quality controlled (Phred score 20)
and adapter trimmed using Trim Galore. Filtered data were
mapped to the human genome (HG19) using TopHat2.
CircRNA expression was quantiﬁed based on a stringent
version of the ﬁnd_circ bioinformatics algorithm [29].
Reads per million (RPM) refers to sequencing reads align-
ing across the particular backsplicing junction normalized to
the total number of raw reads. Circular-to-linear (CTL)
ratios were deﬁned as the number of reads spanning the
backsplicing junction divided by the average number of
linear reads spanning the splice donor- or splice acceptor
sites of the backsplicing junction. In addition, we analyzed
the raw RNA-seq data using another bioinformatics algo-
rithm known as CIRI2 as described previously [30].
Data availability
Raw and processed RNA-seq data have been deposited in
the Gene Expression Omnibus (GEO) database under
accession number [GSE108111].
Sanger sequencing across backsplicing junctions
of selected circRNAs
Complementary DNA (cDNA) synthesis was performed on
500 ng total RNA from the MM cell line, NCI-H929, using
the M-MLV reverse transcriptase (Thermo Fisher Scientiﬁc)
and random primers. The cDNA was diluted ﬁvefold in PCR
grade water and used as template for PCR. The reaction
mixtures consisted of 4 µL template in a total volume of 25 µL
using a 1 × ﬁnal concentration of the Taq Reaction buffer,
500 µM dNTPs, 1 unit Taq DNA Polymerase, recombinant
and a ﬁnal MgCl2 concentration of 1.5mM. Primers (Sup-
plementary Table 2) were used at a ﬁnal concentration of 300
nM. The cycling protocol was initiated by one cycle at 94 °C
for 3 min, followed by 40 PCR cycles at 94 °C for 20 s, 60 °C
for 20 s, and 72 °C for 30 sec and a ﬁnal extension step of 72 °
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C for 7min. Five µL of each PCR product was loaded on 2%
agarose gels stained with SYBR™ Safe DNA Gel Stain
(Thermo Fisher Scientiﬁc) and visualized under UV light after
electrophoresis. The remaining 15 µL of each PCR product
was cleaned up using the QIAquick PCR Puriﬁcation Kit
(Qiagen) and Sanger sequenced in both forward and reverse
directions using the service of GATC (GATC Biotech,
Konstanz, Germany).
Northern blotting
Ten µg of high-quality RNA from the NCI-H929 cell line
was treated with 10U RNase R (Epicentre) or mock treated
for 10 min at 37 °C and loaded on a 1.2% agarose gel. The
gel was run for 2.5 h and RNA was transferred to an
Amersham™ Hybond™-N+membrane (GE Healthcare).
After transfer, the membrane was hybridized with [32 P]-
labeled probes at 55 °C. The membranes were exposed to a
phosphoscreen for 48 h and analyzed in Image Lab™ (Bio
Rad). Probe sequences are listed in Supplementary Table 2.
Due to the small size of circIKZF3, we only designed one
probe targeting its backsplice junction.
NanoString nCounter codeset design and circRNA
expression analyses
A custom CodeSet of capture and reporter probes was
designed to target regions of 100 nucleotides overlaying the
backsplicing junctions of 52 unique circRNAs, each probe
with a target sequence of exactly 50 nucleotides (Supple-
mentary Table 3). In addition, ﬁve linear reference genes
were included. The circRNA targets were selected based on
the RNA-seq data from the MM and MCL cell lines and
included both highly and lowly expressed circRNAs. Two
hundred ng and 400 ng of low- and high-quality RNA,
respectively, were subjected to nCounter™ SPRINT
(NanoString Technologies, Seattle, WA, USA) analysis
according to the manufacturer’s instructions. When ana-
lyzing the data using the nSOLVER 3.0 software (Nano-
String Technologies), background subtraction was
performed using the mean of negative controls, and the
geometric mean of positive controls was used for normal-
ization. A second normalization using the geometric mean
of the four most stable linear reference genes (ACTB,
PUM1, SF3A1 and UBC) was performed. The reference
genes have previously been shown to be stably expressed in
B-cell malignancies [31, 32].
RNase R experiments
Five µg of RNA was either treated with 5U RNase R
(Epicentre) or mock treated. The RNA samples were
denatured for 30 s at 95 °C followed by the addition of a
master mix consisting of RNase R (or nuclease-free water
for the mock treated samples), 1 × ﬁnal concentration of
reaction buffer and RiboLock (Thermo Fischer Scientiﬁc).
Reactions were incubated for 10 min at 37 °C. Following
RNase R or mock treatment, each sample was diluted to a
total volume of 300 µL with nuclease-free water, washed
with one volume of ethanol (96–100%) and applied to an
RNeasy mini spin column (Qiagen) and centrifuged for 15 s
at 10,000 g. Subsequently, two washing steps with 500 µL
buffer RPE were performed, and an additional 2-min cen-
trifugation step was carried out before eluting the samples in
50 µL nuclease-free water. RNA concentrations were stan-
dardized before NanoString analyses.
RT-qPCR analyses
cDNA synthesis was done in duplicate with 1 µg of RNA
from each MCL cell line using the M-MLV Superscript III
reverse transcriptase (Invitrogen, Carlsbad, CA, USA) and
random primers. The cDNA was diluted ﬁvefold and used as
template for qPCR. The reaction mixtures consisted of 2 µL
template in a total volume of 20 µL using a 1 × ﬁnal con-
centration of the 2 × SYBR Green I Master (Roche, Basel,
Switzerland) and primers (Supplementary Table 4) at a ﬁnal
concentration of 500 nM. The cycling protocol was initiated
by 1 cycle at 95 °C for 10 min, followed by 40 PCR cycles at
95 °C for 10 s, 60 °C for 20 s, and 72 °C for 20 s and a melt
curve analysis. Each primer pair was evaluated using serial
dilutions, and experiments were performed according to the
MIQE guidelines [33]. The PCR efﬁciency (E) and quanti-
tative accuracy (Pearson’s correlation coefﬁcients) for each
assay are listed in Supplementary Table 5. The RT-qPCR
data were normalized using the same four reference genes as
used to normalize the NanoString data.
Heat maps and hierarchical cluster analyses
For the heat maps and hierarchical cluster analyses, a
z-score transformation of the normalized counts for each
circRNA was performed. Clustering was done with the
Pearson’s correlation distance metric and the linkage
method called average using the nSOLVER 3.0 software
(NanoString Technologies).
Statistical analyses
All statistical tests were performed using Prism 7 (GraphPad,
La Jolla, CA, USA). The reproducibility between RNA-seq-
and NanoString data, RT-qPCR and NanoString data, as well
as NanoString intra-assay reproducibility, was evaluated
using linear regression. Analyses of 2 × 2 tables were done
using Fisher’s exact tests. All P-values were two-tailed and
considered signiﬁcant if < 0.05.
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Results
RNA-seq proﬁling reveals high expression of
circRNAs in MCL and MM
RNA-seq proﬁling of four different MCL cell lines, REC-1,
Granta-519, UPN2, Z138 and the MM cell line, NCI-H929,
revealed 813, 816, 741, 279 and 619 unique circRNAs,
respectively, all supported by at least ﬁve backsplice
junction-spanning reads using the ﬁnd_circ bioinformatics
algorithm (Fig. 1). CircRNAs composed of two exons were
most frequent in all cell lines (Supplementary Figure 2).
The highest percentage (12.4%) of circRNAs, with
expression levels higher than their respective host genes,
was observed in Z138, whereas the lowest percentage
(7.5%) was observed in Granta-519 (Supplementary Fig-
ure 2). Host genes producing a single circRNA were most
frequent in all cell lines. However, some genes produced
several unique circRNAs, including ATM, XPO1 and
WHSC1, which are genes involved in lymphomagenesis
(Supplementary Figure 2).
Interestingly, we found several circRNAs, which
have previously been implicated in cancer, including ciRS-7
[34–36], circHIPK3 [7, 37], circCCDC66 [38], circFBXW7
[16], circSMARCA5 [39, 40], circCDYL [37] and cir-
cZKSCAN1 [41]. We also detected circRNAs from genes
involved in lymphomagenesis and the development of MM,
including FOXP1 [42], SETD3 [43], EZH2 [44], ATM [45],
XPO1 [46], IKZF3 [47], CD11A (ITGAL) [48] and WHSC1
(MMSET) [49]. The circRNA derived from IKZF3 is not
listed in circBase [50] and has, to our knowledge, not pre-
viously been reported. Several of these circRNAs were
expressed at higher levels than the corresponding linear host
genes (Fig. 2).
The RNA-seq data were validated for several of the
circRNAs, including the novel circRNA from IKZF3, by
RT-PCR with divergent primers (Fig. 3a, b) and Sanger
sequencing across the backsplicing junctions (Fig. 3c).
Northern blotting was also successfully performed for the
novel circRNA from IKZF3 and for the second highest
expressed circRNA in NCI-H929, circRP11-255H23.2,
which has not previously been conﬁrmed by northern
blotting (Fig. 3d).
CircRNA expression proﬁles in cell lines from various
B-cell malignancies
Based on the RNA-seq data, we designed NanoString
assays targeting 52 circRNA candidates, mainly focusing on
circRNAs previously implicated in other cancers and cir-
cRNAs produced from host genes involved in lymphoma-
genesis. These assays were used to elucidate the expression
of circRNA in B-cell malignancies by analyzing RNA from
15 different cell lines, including four DLBCL, two BL, four
MCL and ﬁve MM. Four of the ﬁve MM cell lines clustered
separately from all the other cell lines, whereas one
(MOLP2) clustered together with the DLBCL cell line of
GCB-type (HT) and the two BL cell lines (Raji and Ramos).
MOLP2 is the only MM cell line expressing IgD, indicating
origin from a GC B-cell, which is also the origin of BL and
DLBCL of the GCB-type. In addition, the DLBCL cell lines
of ABC-type (OCI-Ly3 and U2932) clustered together, and
the four MCL cell lines clustered together. The novel cir-
cRNA from IKZF3 was highly expressed in NCI-H929
(conﬁrming the RNA-seq data) and also relatively abundant
in MOLP2 and in OCI-Ly3 and U2932 (Fig. 4).
The nanostring assays are speciﬁc for circRNA
detection
RNase R experiments were performed to investigate whe-
ther the NanoString assays were speciﬁc for circRNA
detection. RNA samples from two MCL cell lines (Granta-
519 and Z138) were treated with RNase R or mock treated.
Among the 52 circRNAs analyzed, only three and ﬁve
species were not enriched by more than twofold upon
RNase R treatment in Granta-519 and Z138, respectively.
(Fig. 5). Unexpressed circRNAs are not expected to be
enriched. As an example, ciRS-7 was clearly enriched in
Granta-519 where it is highly expressed, but not in Z138,
where it is expressed at a very low level. The only circRNA
that was expressed in both cell lines and clearly not resistant
to RNase R was circZNF91. The ﬁve linear RNAs analyzed
by NanoString were degraded to various extents as expec-
ted. Overall, an average increase in circRNA expression of
approximately sixfold was observed for the circRNAs,
whereas the linear RNAs were on average decreased by
approximately fourfold.
The nanostring assays provide reproducible data
To test the reproducibility of the NanoString technology for
circRNA detection, two RNA samples of high and low
quality in terms of RNA degradation were analyzed twice
on different days. A high correlation between the Nano-
String data from individual replicates were observed for
both high- and low-quality RNA samples (Supplementary
Figure 3).
Correlation between nanostring data from
high- and low-quality RNA
To investigate how well data from samples of high quality
compare with data from samples of low quality, we
formalin-ﬁxed and parafﬁn-embedded cells from each of the
four MCL cell lines. Quality assessments conﬁrmed that
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RNA from the FFPE cells was degraded (Supplementary
Figure 1). Nevertheless, a good correlation between the-
NanoString data from high- and low-quality RNA
was observed for all four cell lines (Supplementary
Figure 4). In addition, unsupervised hierarchical cluster
analyses clearly separated the samples according to cell line
and not according to RNA quality (Supplementary
Figure 5).
Fig. 1 CircRNAs are highly
abundant in MM and MCL cell
lines. a-e CircRNA species in
the cell lines REC-1 a, Granta-
519 b, UPN2 c, Z138 d and
NCI-H929 e supported by at
least ﬁve reads are displayed.
The number of circRNAs (y
axis) detected by a speciﬁc
number of reads in RNA-seq (x
axis) is shown. Host genes of
circRNA species of particular
interest are indicated
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Correlation between nanostring data from paired
fresh frozen and FFPE patient samples
NanoString data from paired fresh frozen and FFPE tissue
samples from patients with various B-cell malignancies
were analyzed to investigate how well the technology per-
forms using old archival FFPE tissue samples. We calcu-
lated DV 200 values, a measure of the percentage of RNA
fragments above 200 nucleotides, to analyze the RNA
quality of the samples (Supplementary Table 1). Four FFPE
samples were severely degraded (DV 200 < 0.33), whereas
the remaining FFPE samples had DV 200 values above
0.40. Despite the poor RNA quality, a relatively high cor-
relation between the NanoString data from high- and low-
quality RNA was observed for all sample pairs (Supple-
mentary Figure 6), with the exception of one pair (patient
22), for which a normalization ﬂag in the NanoString ana-
lyses indicated that the data was of poor quality. This
sample pair was therefore removed from further analyses.
Data from the FFPE samples with DV 200 values above
0.40 correlated better with data from their respective paired
fresh frozen sample (mean R2 value: 0.85, range: 0.70–0.97)
compared with sample pairs for which the FFPE sample had
a DV 200 value below 0.33 (mean R2 value: 0.69, range:
0.57–0.83). Finally, unsupervised hierarchical cluster ana-
lyses, using samples with DV 200 values above 0.40,
clearly separated the samples according to individual
patients and not according to RNA quality (Supplementary
Figure 7).
Comparison of nanostring data with RNA-seq- and
RT-qPCR data
Highly signiﬁcant correlations between Nanostring- and
RNA-seq data (analyzed by ﬁnd_circ) were observed
(Fig. 6, left panel and Supplementary Figure 8, left panel).
However, a bias was observed whereby the expression of
speciﬁc circRNAs was systematically estimated to be either
higher or lower by RNA-seq relative to NanoString in all
cell lines. These circRNAs included circCDYL, circVRK1,
circSMARCA5, circCCDC66, circZKSCAN1 and cir-
cHIPK3 (Supplementary Figure 9). Therefore, to examine
their expression by a third method, we designed RT-qPCR
assays for these circRNAs and analyzed the MCL cell
lines. For all, except circVRK1, we observed a good cor-
relation between NanoString- and RT-qPCR data with no
systematic over- or underestimations of the expression
levels (Supplementary Figure 10). To investigate if the
systematic differences between RNA-seq and NanoString
relate to the bioinformatics algorithm used to analyze the
RNA-seq data, we also quantiﬁed circRNA expression data
using CIRI2 [30]. The correlations between ﬁnd_circ and
CIRI2 were not perfect, but overall better than observed
when comparing NanoString- and ﬁnd_circ data. There-
fore, the selection of bioinformatic algorithm does not
appear to explain the majority of the bias. However,
circVRK1 was consistently estimated to be lower expres-
sed by CIRI2 compared with ﬁnd_circ (Supplementary
Figure 11). Thus, the CIRI2 data was in better agreement
with the NanoString data than ﬁnd_circ for this particular
circRNA.
We also analyzed the NanoString- and RNA-seq data (by
ﬁnd_circ) as dichotomous variables, using pre-deﬁned cut-
offs for grouping the circRNAs into expressed or not
expressed. We observed a signiﬁcant correlation between
the data for all cell lines (Fig. 6, right panel and Supple-
mentary Figure 8, right panel). To further analyze the cir-
cRNAs for which RNA-seq and NanoString data differed,
we used the results from the RNase R experiments on Z138
and Granta-519. In Z138, six circRNAs were detected only
by NanoString, all of which were enriched in the RNase R
experiment (deﬁned as an increase of >50 raw counts), and
four were detected only by RNA-seq, of which only one
(circFOXP1) was enriched in the RNase R experiment
(Fig. 6a, right panel). In Granta-519, six circRNAs were
detected only by NanoString and one was detected only by
RNA-seq. Five of the six circRNAs detected only by
NanoString were enriched in the RNase R experiment. This
also applied to the one circRNA (circFOXP1) only detected
by RNA-seq (Fig. 6b, right panel). RT-qPCR conﬁrmed that
circFOXP1 is expressed at low levels in both Granta-519
and Z138 (Supplementary Figure 12), and despite being
below the arbitrary cut-off, it was indeed expressed above
Fig. 2 Barplot showing the circular-to-linear (CTL) ratios of 14 dif-
ferent cancer-related circRNAs in four different mantle cell lymphoma
(MCL) cell lines and one multiple myeloma (MM) cell line (NCI-
H929) color-coded as indicated. Several of these circRNAs were
expressed at a higher level than the corresponding linear host genes
(CTL ratio > 1) in at least one of the cell lines studied. For ciRS-7,
there was no linear reads spanning the splice donor and splice acceptor
sites of the backsplicing junction. Thus, no CTL ratios could be cal-
culated for this particular circRNA
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background in the NanoString data (data not shown). RT-
qPCR also conﬁrmed that circASXL1 and circCHD7
are expressed in Granta-519 and Z138, respectively,
although not being detected by ﬁnd_circ. These two
circRNAs were also detected by CIRI2. In addition,
circSLC8A1, which was detected by ﬁnd_circ and not by
NanoString in Z138, could not be detected by RT-qPCR
in this cell line (Supplementary Figure 12).
Finally, for some of the RT-qPCR assays we observed
concatemers, which are likely formed by rolling circle
ampliﬁcation during the RT step. This applied to the assays
targeting circZKSCAN1, circSMARCA5, circASXL1 and
Fig. 3 Validation of RNA-seq data for selected circRNAs using PCR
with divergent primers and Sanger sequencing. a Schematic repre-
sentation of divergent PCR primer design that ensures circular RNA-
speciﬁc ampliﬁcation. b Agarose gel electrophoresis of circRNA-
speciﬁc PCR on six different circRNAs as shown. The expected
amplicon size is denoted in parenthesis, and 100-bp molecular marker
is included on both sides of the gel. c For all six circRNAs analyzed,
Sanger sequencing chromatograms across the backsplicing junction
are shown. Arrows indicate the exon-exon junctions. d Northern
blotting for circRP11-255H23.2 and circIKZF3. Due to the small size
of circIKZF3, we only designed one probe targeting its backsplice
junction
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circFOXP1. For circFOXP1, melting curve analysis
revealed two peaks at 77 °C and 85 °C, respectively. These
corresponded to two products detected using gel electro-
phoresis, namely the expected amplicon of 49 bp and a
product of approximately 600 bp. Because the spliced
length of circFOXP1 is 587 bp, the second product is likely
to represent a concatemer resulting from rolling circle
ampliﬁcation (Supplementary Figure 13).
Discussion
Reliable detection and quantiﬁcation of circRNAs is cur-
rently hampered by the risk of introducing experimental
bias and artifacts as most available methods, including
RNA-seq, microarray and RT-qPCR, employ RT and/or
PCR ampliﬁcation. For this reason, there is a high demand
for novel reliable methods for accurate quantiﬁcation of
circRNAs.
The NanoString technology is enzyme-free and, there-
fore, not prone to artifacts and bias associated with RT and
PCR ampliﬁcation. It is a digital counting method, which
allow up to 800 targets to be investigated simultaneously
with minimal hands-on-time. Following over-night hybri-
dization, results can be obtained within approximately 6 h
and the downstream analyses do not require bioinformatic
expertise and can be completed on a standard laptop. For
these reasons, the NanoString technology is easily imple-
mented in a clinical setting and is already used clinically for
breast cancer prognostication based on a 50-gene mRNA
test [51], which works well on RNA isolated from FFPE
tissue sections [52].
The expression of circRNA molecules in B-cell malig-
nancies has not previously been explored and there is a lack
of reliable high-throughput methodologies for investigating
circRNA expression proﬁles in low-quality RNA samples
from FFPE tissues. Therefore, we decided to explore the
potential of the NanoString technology for quantiﬁcation of
circRNA molecules in both high- and low-quality RNA
samples from malignant cell lines and samples from patients
with B-cell malignancies.
First, we performed RNA-seq of MM and MCL cell lines
to proﬁle circRNA expression and found several circRNAs,
which have previously been implicated in cancer, indicating
that circRNAs may play important roles in the pathogenesis
of these diseases. Interestingly, we also detected circRNAs
from genes involved in lymphomagenesis and the devel-
opment of MM, including a circRNA derived from the
IKZF3 gene, which is not listed in circBase [50] and, to our
knowledge, has not previously been reported.
We designed a panel of NanoString assays targeting the
unique backsplicing junctions of 52 circRNAs based on the
RNA-seq data, and showed that circRNA expression pro-
ﬁles can distinguish different B-cell malignancies. The
speciﬁcity of our assays for circRNAs was addressed by
treating samples with RNase R, and upon treatment we
observed enrichment for all expressed circRNAs except
circZNF91, whereas the linear mRNA targets that we used
as reference genes in our study were degraded to various
extents as expected. Regarding circZNF91, Sanger
sequencing across the backsplicing junction was successful
and it has previously been observed that particular cir-
cRNAs are sensitive to RNase R [25]. Because some
Fig. 4 Hierarchical cluster analysis of NanoString data from 15
malignant B-cell lines. Heatmap showing expression and clustering of
52 circRNAs (rows) from 15 malignant B-cell lines (columns). The
cell lines comprise MM cell lines (JJN3, NCI-H929, OPM2, RPMI-
8826 and MOLP2), MCL cell lines (UPN2, Granta-519, REC-1 and
Z138), BL cell lines (Raji and Ramos), DLBCL cell lines, ABC-type
(OCI-Ly3 and U2932) and DLBCL cell lines, GCB-type (HT and
Toledo)
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circRNAs have been shown to be RNase R sensitive and the
efﬁciency of RNase R treatments to remove linear RNA can
vary [4], this data do not provide stringent proof that the
assays solely target circular transcripts. However, the
observed degree of enrichment in circRNA targets corre-
sponds to what we expected and strongly supports that our
NanoString assays are speciﬁc for circRNA detection.
Furthermore, reporter and capture probes must bind
immediately adjacent to one another to allow efﬁcient
binding of the hybridized complex to a streptavidin-coated
slide cartridge and produce a target-speciﬁc signal. In the
presence of a canonical linear transcript, the probes will
bind with a gap between them, as well as in the opposite
orientation required for proper stretching of the reporter
molecule by electrophoresis and imaging [27].
We found that NanoString- and RNA-seq data did not
correlate particularly well for all circRNAs, rather a sys-
tematic over- or underestimation of circRNA levels for
some circRNAs was observed. Nevertheless, RT-qPCR data
for these selected circRNAs generally correlated better with
NanoString data. It may seem contradictory to use a
method, which rely on RT and PCR for comparison.
However, there are, to our knowledge, currently no other
enzyme-free methods available for accurate circRNA
quantiﬁcation. Moreover, it has been shown that different
polymerases introduce different artifacts/bias [53], thus, it
was not expected that we would be able to reproduce the
systematic bias observed between NanoString and RNA-seq
when using RT-qPCR. Because variation can occur when
using different bioinformatic algorithms for circRNA
quantiﬁcation in RNA-seq data [54], we also analyzed the
data using another algorithm known as CIRI2 [30]. CIRI2
and ﬁnd_circ correlated quite well but there were a few
exceptions. For instance, ﬁnd_circ did not detect the pre-
sence of circDDX21 in any of the samples, whereas CIRI2
did, and vice versa for circIKZF3. Nevertheless, most of the
biases observed are likely of experimental nature relating to
the RT and PCR ampliﬁcation during library preparation for
Fig. 5 NanoString analysis on RNase R-treated samples. a, c Barplot
depicting relative raw counts obtained from NanoString analysis of 52
circRNAs (green) and ﬁve linear control mRNAs (blue) in mock and
RNAse R-treated samples from cell lines Granta-519 a and Z138 c. b,
d From a and c, the fold-change (RNAse R treated/mock treated) is
shown for transcripts for which RNAse R treated > mock treated,
whereas (mock treated/RNAse R treated)*(−1) is shown for transcripts
for which RNAse R treated < mock treated
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RNA-seq. We also found that most circRNAs detected by
NanoString and not by RNA-seq were enriched in the
RNase R experiments, whereas most of the circRNAs
detected only by RNA-seq were not. Thus, our data indicate
that the NanoString technology may be more accurate than
RNA-seq for circRNA quantiﬁcation and more sensitive
and speciﬁc for the detection of circRNAs expressed at low
levels.
Finally, we studied circRNA expression proﬁles in
archival FFPE tissue samples from patients with various
B-cell malignancies from which a fresh frozen sample was
also available. The RNA extracted from these samples had
RIN values between 1.5 and 2.5 indicating that the RNA
was severely degraded. However, we observed very good
correlations between the NanoString data obtained from
these samples and the RNA samples from the paired fresh
frozen tissues. The correlation was particularly good when
the RNA from FFPE samples had a DV 200 value above
0.40. When performing hierarchical cluster analysis on
the NanoString data from these and the paired samples,
we observed a clear separation according to individual
patients and not according to RNA quality. In contrast, the
patient samples did not cluster according to diagnoses as
could be expected from the data on the cell lines. This
may be explained by the fact that patient samples have
different background levels of RNA from normal cells as
no micro- or macro dissections were performed in this
study.
Currently, NanoString assays for circRNA quantiﬁcation
have to be custom made and RNA-seq is still the method of
choice for the discovery of novel circRNAs. In addition,
RNA-seq may also reveal internal splicing patterns of cir-
cRNAs when depleting linear RNA by an RNase R treat-
ment followed by polyadenylation and poly(A)+ RNA
depletion [55].
In conclusion, we have shown that the NanoString
technology is sensitive, speciﬁc and quantitatively accurate
for the detection of circRNA in both high- and low-quality
RNA samples from cell lines and samples from patients
with B-cell malignancies. Because this technology does not
rely on RT and PCR ampliﬁcation, which are known to
create artifacts, it has the potential to become the gold
standard method for circRNA quantiﬁcation.
Supplementary Information accompanies the paper on
the Laboratory Investigation website (http://www.nature.
com/labinvest/).
Fig. 6 Comparison of circRNA expression data by NanoString and
RNA-seq for the cell lines where RNase R experiments were per-
formed. a, b Correlation between RPM and NanoString-derived nor-
malized counts from Z138 a and Granta-519 b cell lines with
corresponding linear regression statistics and R-squared values (left
panel). Middle panel shows 2 × 2 contingency table using pre-deﬁned
expression stratiﬁcation as shown. NanoString- or RNA-seq-speciﬁc
detection is color-coded orange or green, respectively. RNAse R
sensitivity for the NanoString (orange bars) or RNA-seq-speciﬁc cir-
cRNAs (green bars) are shown to the right by relative counts between
mock and RNAse R-treated samples for Z138 a and Granta-519
b. circASXL1 was an extreme outlier and removed from the analyses
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